News from Oblita and partners
Follow our latest newsThe beginnings of Oblita Therapeutic’s molecule D121
Preclinical research demonstrates D121 outcompetes miltefosine
TT4CL is moving forward the R&D of a new molecule, D121, for cutaneous leishmaniasis by some more preclinical research as well as a phase 1 study
Development of a new leishmaniasis drug wins EU funding
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and their social and economic impacts. Funding from Horizon 2020,...